Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 2611 of 3330
Next
>>
>
65251 to 65275 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Perturbagen Target	Perturbagen Class	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
MCF 10A	NM	Basal B	Selumetinib	MEK	MAPK	0.000128	uM	11056.155	0.9863	0.9906	2.9269
MCF 10A	NM	Basal B	Selumetinib	MEK	MAPK	0.00064	uM	11056.155	1.0475	1.0319	2.9269
MCF 10A	NM	Basal B	Selumetinib	MEK	MAPK	0.0032	uM	11056.155	0.9687	0.9784	2.9269
MCF 10A	NM	Basal B	Selumetinib	MEK	MAPK	0.016	uM	11056.155	0.9066	0.9341	2.9269
MCF 10A	NM	Basal B	Selumetinib	MEK	MAPK	0.08	uM	11056.155	0.5928	0.6728	2.9269
MCF 10A	NM	Basal B	Selumetinib	MEK	MAPK	0.4	uM	11056.155	0.5098	0.5888	2.9269
MCF 10A	NM	Basal B	Selumetinib	MEK	MAPK	2	uM	11056.155	0.3334	0.3742	2.9269
MCF 10A	NM	Basal B	Selumetinib	MEK	MAPK	10	uM	11056.155	0.3002	0.3259	2.9269
MCF 10A	NM	Basal B	Selumetinib	MEK	MAPK	50	uM	11056.155	0.2581	0.2591	2.9269
MCF 10F	NM	-	Selumetinib	MEK	MAPK	0.000128	uM	12254.155	1.0465	1.0508	1.8150
MCF 10F	NM	-	Selumetinib	MEK	MAPK	0.00064	uM	12254.155	1.0084	1.0093	1.8150
MCF 10F	NM	-	Selumetinib	MEK	MAPK	0.0032	uM	12254.155	1.0378	1.0413	1.8150
MCF 10F	NM	-	Selumetinib	MEK	MAPK	0.016	uM	12254.155	0.9605	0.9561	1.8150
MCF 10F	NM	-	Selumetinib	MEK	MAPK	0.08	uM	12254.155	0.9555	0.9505	1.8150
MCF 10F	NM	-	Selumetinib	MEK	MAPK	0.4	uM	12254.155	0.8472	0.8254	1.8150
MCF 10F	NM	-	Selumetinib	MEK	MAPK	2	uM	12254.155	0.6431	0.5682	1.8150
MCF 10F	NM	-	Selumetinib	MEK	MAPK	10	uM	12254.155	0.5228	0.3991	1.8150
MCF 10F	NM	-	Selumetinib	MEK	MAPK	50	uM	12254.155	0.4523	0.2918	1.8150
MCF12A	NM	Basal B	Selumetinib	MEK	MAPK	0.000128	uM	10817.155	0.9614	0.9515	1.6045
MCF12A	NM	Basal B	Selumetinib	MEK	MAPK	0.00064	uM	10817.155	0.9598	0.9495	1.6045
MCF12A	NM	Basal B	Selumetinib	MEK	MAPK	0.0032	uM	10817.155	0.9598	0.9495	1.6045
MCF12A	NM	Basal B	Selumetinib	MEK	MAPK	0.016	uM	10817.155	0.8852	0.8537	1.6045
MCF12A	NM	Basal B	Selumetinib	MEK	MAPK	0.08	uM	10817.155	0.7332	0.6483	1.6045
MCF12A	NM	Basal B	Selumetinib	MEK	MAPK	0.4	uM	10817.155	0.5925	0.4433	1.6045
MCF12A	NM	Basal B	Selumetinib	MEK	MAPK	2	uM	10817.155	0.4205	0.1656	1.6045

|<
<<
Previous
Page 2611 of 3330
Next
>>
>
65251 to 65275 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)